title: [Changes in bone metabolism markers in women after Roux-en-Y gastric bypass].
abstract: OBJECTIVE
  To evaluate bone turnover markers and bone mineral density (BMD) in women after Roux-en-Y (RYGB) gastric bypass.
  
  
  METHODS
  In a cross-sectional study, 48 women post-RYGB after three years, and 41 healthy women were evaluated.
  
  
  METHODS
  body mass index (BMI); physical activity; food intake; serum levels of calcium, phosphorus, magnesium, alkaline phosphatase, C-terminal telopeptide (CTX), intact parathyroid hormone (PTH), 25-hydroxyvitamin D (25OHD), osteocalcin, urinary calcium and BMD.
  
  
  RESULTS
  Significantly higher levels were observed for osteocalcin (p < 0.001), CTX (p < 0.001), and PTH (p < 0.001) in the RYGB group when compared with the control group; 25OHD deficiency/insufficiency was more frequent in the RYGB group (p = 0.010), even after adjusted for nutritional status, and it was associated with secondary hyperparathyroidism (p = 0.025); there was no difference in BMD between the groups. Energy (p = 0.036) and protein intake (p = 0.004) were lower in the RYGB group.
  
  
  CONCLUSIONS
  Patients submitted to RYGB showed a significantly higher frequency of vitamin D deficiency, secondary hyperparathyroidism, and increase in bone remodeling markers, with no difference in BMD status.
authors.affiliation: Faculdade de Medicina do ABC, (FMABC). Serviço de Nutrição e Dietética, Centro Hospitalar do Município de Santo André e Curso de Pós-Graduação em Nutrição Clínica e Metabolismo, Faculdade de Pós-Graduação, Escola Técnica (CBES), Brasil.
authors.forename: Maria Tereza Amaral dos
authors.initials: MT
authors.lastname: Santos
authors.forename: Fabíola Isabel Suano de
authors.initials: FI
authors.lastname: Souza
authors.forename: Fernando Luiz Affonso
authors.initials: FL
authors.lastname: Fonseca
authors.forename: Marise
authors.initials: M
authors.lastname: Lazaretti-Castro
authors.forename: Roseli Oselka Saccardo
authors.initials: RO
authors.lastname: Sarni
mesh_terms: D000328:Adult; D015415:Biomarkers / Q000378:metabolism*; D015519:Bone Density; D016723:Bone Remodeling; D001842:Bone and Bones / Q000378:metabolism*; D002118:Calcium / Q000008:administration & dosage / Q000032:analysis; D016022:Case-Control Studies; D019587:Dietary Supplements; D005260:Female; D015390:Gastric Bypass / Q000009:adverse effects; D006801:Humans; D006962:Hyperparathyroidism, Secondary / Q000097:blood; D008875:Middle Aged; D009765:Obesity / Q000601:surgery; D015675:Osteocalcin / Q000378:metabolism; D010024:Osteoporosis / Q000517:prevention & control; D014807:Vitamin D / Q000031:analogs & derivatives / Q000378:metabolism; D014808:Vitamin D Deficiency / Q000097:blood
chemical_list: D015415:Biomarkers; D015675:Osteocalcin; D014807:Vitamin D; C104450:25-hydroxyvitamin D; D002118:Calcium